Biodexa Pharmaceuticals Plc (BDRX) stock
BDRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.24−0.16 (-6.67%)
Close on Nov 16, 2026Market cap $5.06MP/E –Yield –
Biodexa Pharmaceuticals price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Biodexa Pharmaceuticals's price to sales ratio was 8.8× on Feb 28, 2025, against 0.7× a year earlier. Over the last 5 years it ranged from 0.7× to 490.2×, with a median of 71.5×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2025 | Feb 28, 2025 | 8.8× | −2.0 |
| 2024 | Dec 31, 2024 | 10.7× | +9.2 |
| 2023 | Dec 29, 2023 | 1.5× | −336.2 |
| 2021 | Jan 29, 2021 | 337.7× | +39.9 |
| 2020 | Dec 31, 2020 | 297.8× | +265.0 |
| 2019 | Dec 31, 2019 | 32.8× | −93.3 |
| 2018 | Dec 31, 2018 | 126.0× | −211.5 |
| 2017 | Dec 29, 2017 | 337.6× | – |
See a number that looks wrong?